Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

Announcement on Voluntary Disclosure of the Approval Notice for Drug Clinical Trial of SI-B036 Bispecific Antibody Injection for Treatment of Locally Advanced or Metastatic Solid Tumors

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Approval Notice for Drug Clinical Trial of SI-B036 Bispecific Antibody Injection for Treatment of Locally Advanced or Metastatic Solid Tumors

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis